FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) announced expansion of its wound care platform into acute and chronic burn treatment using its proprietary fibroblast spheroid therapy CYWC628.
In preclinical burn models, CYWC628 increased tissue IL-10 nearly four-fold and reduced IL-1B, suggesting faster, higher-quality healing; company plans to advance toward clinical development and integrate burn work into its wound care strategy.
The release cites a global burn care market of $2.55B today, growing to $3.35B by 2030.
Positive
- IL-10 tissue levels increased ~4x in preclinical burn models
- IL-1B inflammation showed a significant reduction in preclinical burn tissue
- Addressable market cited at $2.55B, growing to $3.35B by 2030
Negative
- Preclinical only: results are not yet from human clinical trials
- No clinical timeline or trial start date disclosed for CYWC628
News Market Reaction – FBLG
On the day this news was published, FBLG declined 0.03%, reflecting a mild negative market reaction. Argus tracked a trough of -23.4% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $7K from the company's valuation, bringing the market cap to $23M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FBLG fell 14.11% while key peers were mixed: GDTC +8.9%, LIXT +12.73%, NRXS +0.78%, ICU -0.72%, CRIS 0%. Only AKTX appeared on the momentum scanner, up 3.45% without news. The move in FBLG appears stock-specific rather than a coordinated biotech sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Clinical trial progress | Positive | +11.6% | Completed site onboarding for Phase 1/2 CYWC628 diabetic foot ulcer trial. |
| Mar 02 | IP / patent win | Positive | +27.7% | New U.S. patent issued covering fibroblast cell therapy for osteoporosis. |
| Feb 26 | Conference appearance | Positive | +7.4% | CEO presentation and meetings at BIO Investment & Growth Summit. |
| Feb 24 | Earnings and update | Neutral | -1.6% | Reported 2025 results, highlighted cash position, net loss, and pipeline milestones. |
| Feb 23 | Nasdaq compliance | Negative | +2.0% | Received Nasdaq extension with strict equity and minimum bid price requirements. |
Recent news has often triggered upside on pipeline and IP updates, while listing/financial items show more mixed and sometimes contrary price reactions.
Over the past few weeks, FibroBiologics has reported several milestones: completion of site onboarding for a Phase 1/2 trial of CYWC628 on Mar 5 2026, issuance of a U.S. osteoporosis patent on Feb 10 2026 (announced Mar 2), and a CEO presentation at the BIO Investment & Growth Summit. Financial results for full-year 2025 highlighted cash of $4.9M and a net loss of $18.6M. The company also secured a Nasdaq compliance extension with specific equity and bid-price targets. Today’s burn-care expansion builds on the same fibroblast spheroid platform featured in recent clinical updates.
Market Pulse Summary
This announcement expands FibroBiologics’ fibroblast spheroid platform into acute and chronic burn care, citing nearly four-fold IL-10 increases and reduced IL-1B in preclinical models. It positions CYWC628 within a global burn market estimated at $2.55B today and $3.35B by 2030. In context of recent CYWC628 trial preparations and broader pipeline activity, investors may watch for timing of first-in-human burn studies and more granular efficacy and safety data.
Key Terms
fibroblast spheroid medical
cytokine medical
IL-10 medical
IL-1B medical
AI-generated analysis. Not financial advice.
HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using proprietary fibroblast spheroid technology, today announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries.
Building on its investigational fibroblast spheroid-based programs in chronic wound healing, FibroBiologics is applying the same core technology to address the significant unmet medical needs in burn care, where current standards of care often result in prolonged healing, multiple procedures, and substantial scarring.
In preclinical burn models, treatment with proprietary fibroblast spheroids (CYWC628) was associated with nearly a four-fold increase in tissue-level IL-10, a cytokine known to support tissue repair and wound healing in skin.
Additionally, CYWC628 drove a significant reduction in IL-1B, a key driver of inflammation in burn wounds, further supporting the potential of the platform to promote better, faster healing in patients with severe burns.
These findings suggest that CYWC628 may both accelerate wound closure and improve the quality of healed tissue by simultaneously promoting regeneration and dialing down harmful inflammation.
“These new burn data reinforce our conviction that fibroblast spheroids can reshape how serious wounds are treated,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “By combining strong signals of tissue repair with meaningful reductions in inflammatory markers, CYWC628 positions us to address a large, underserved market in burn care and create significant benefit for patients. We believe that a targeted, cell-based approach has the potential to improve healing outcomes, reduce complications, and ultimately change the standard of care for burn patients worldwide.”
“From a scientific standpoint, seeing nearly a four-fold increase in IL-10 alongside a significant reduction in IL-1B in burn tissue is highly encouraging,” noted Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “These tissue-level biomarker changes align with the type of regenerative, pro-healing environment we are aiming to create in complex wounds and give us confidence as we advance CYWC628 toward clinical development in burn patients.”
Burns remain a major global health concern with significant unmet needs, with the worldwide burn care market estimated to be
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.
For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for FibroBiologics’ research and development programs, the robustness, progress, and momentum of FibroBiologics’ research and development program, the potential indications for FibroBiologics’ programs, the potential of product candidates as scalable platform technologies, estimates of market size, and the potential clinical benefits of fibroblasts and fibroblast-derived materials, including changing the standard of care for burn patients worldwide. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; and (c) the unpredictable relationship between R&D and preclinical results and clinical study results. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What preclinical burn results did FibroBiologics (FBLG) announce on March 12, 2026?
How might CYWC628 affect burn healing according to FibroBiologics (FBLG)?
Does FibroBiologics (FBLG) report clinical trial dates for its burn program?
What market opportunity did FibroBiologics (FBLG) cite for burn care on March 12, 2026?
Are FibroBiologics’ burn findings from human patients or animal/preclinical models?
What are the immediate next steps FibroBiologics (FBLG) described for CYWC628 in burn care?
